Detalhe da pesquisa
1.
Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.
Lancet
; 384(9941): 414-26, 2014 Aug 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-24907224
2.
Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C.
Gastroenterology
; 146(3): 744-753.e3, 2014 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24316262
3.
The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C.
Hepatology
; 55(3): 749-58, 2012 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-22006408
4.
Alcohol-associated bowel disease: new insights into pathogenesis.
eGastroenterology
; 1(1)2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37662449
5.
Safety of peginterferon alfa-2a plus ribavirin in a large multinational cohort of chronic hepatitis C patients.
Liver Int
; 32(8): 1270-7, 2012 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-22621707
6.
Kupffer cell activation is a causal factor for hepatic insulin resistance.
Am J Physiol Gastrointest Liver Physiol
; 298(1): G107-16, 2010 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-19875703
7.
Clodronate liposomes: all sites of injection are not equal.
Hepatology
; 51(2): 721-2; author reply 722, 2010 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-20101758
8.
Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.
Vaccine
; 26(10): 1375-86, 2008 Mar 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-18272264
9.
A health economic model to assess the cost-effectiveness of pegylated interferon alpha-2a and ribavirin in patients with moderate chronic hepatitis C and persistently normal alanine aminotransferase levels.
Acta Gastroenterol Belg
; 70(2): 177-87, 2007.
Artigo
em Inglês
| MEDLINE | ID: mdl-17715631
10.
Phase 2 study of the combination of merimepodib with peginterferon-alpha2b, and ribavirin in nonresponders to previous therapy for chronic hepatitis C.
J Hepatol
; 47(4): 476-83, 2007 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-17629590
11.
Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia.
J Hepatol
; 44(1): 97-103, 2006 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-16290907
12.
Oral fluid as a medium for the detection of hepatitis B surface antigen.
J Med Virol
; 77(1): 53-6, 2005 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-16032713